Slides
Page 1
Third Quarter 2026 Earnings Investor Presentation October 29, 2026
Page 2
This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2026 guidance, strategic and growth opportunities, other expectations and other non-historical information. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” “vision,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control and are subject to various risks and uncertainties, including those described below. Among other things, there can be no assurance that Omnicell’s actual results will not differ, perhaps substantially, from the targets and expectations contained in this presentation. Such statements also include, but are not limited to, Omnicell’s projected product bookings, annual recurring revenues, revenues, including product, service, technical services and SaaS and Expert Services revenues, respectively, non-GAAP EBITDA, and non-GAAP earnings per share; expectations regarding demand for, and customer interest in, our products and services, expectations regarding our planned and existing products and services, developing new or enhancing existing products and solutions, and the related objectives and expected benefits (and any implied financial impact); our ability to maintain focus on operational discipline, execute against strategic priorities, and deliver sustainable and profitable growth; our ability to expand market presence, scale recurring revenue and accelerate our technology platform; the ability for our next-generation platform to support our customers’ needs; the long-term opportunity the next-generation platform represents and statements about Omnicell’s strategy, plans, objectives, vision, purpose and guiding principles, opportunities, goals, including its innovation, environment, social and governance goals and strategies, market or Company outlook, planned investments, and growth opportunities. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including longer timeframes for purchasing decisions and entering into agreements for our products or solutions, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) Omnicell’s ability to successfully achieve anticipated growth targets or market adoption, (v) delays in installations of our medication management solutions or our more complex medication packaging systems, including the variability and difficulty in predicting purchasing decisions, for both current customers and competitive conversion opportunities being, difficulty forecasting product bookings due to the size and mix of potential customer opportunities or that the announcement of Titan XT may influence or impact purchasing decisions, including the timing of those decisions, (vi) delays, technical challenges and unexpected or greater than anticipated expenses associated with developing new products and services or failing to achieve technological or economic feasibility, obtain regulatory approval or gain market acceptance, (vii) the potential impact of periods of significant volatility due to geopolitical developments, (viii) the risk of increased credit, collection, and operational challenges from providing lease financing options to our customers, (ix) risks related to the incorporation of artificial intelligence technologies, including generative or agentic AI technologies, into our products, services and processes or our vendors offerings, (x) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xi) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (xii) Omnicell’s ability to meet the demands of, or maintain relationships with, GPOs and its institutional, retail, and specialty pharmacy customers, (xiii) the inability to secure or maintain access to existing and future specialty drugs or pharmacy provider networks for our specialty pharmacy customers, (xiv) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (xv) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses or technologies and successfully integrate such acquisitions, (xvi) Omnicell’s substantial debt, (xvii) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same, (xviii) changes to the 340B Program, (xix) our international operations may subject us to additional risks, including from the impact of tariffs, (xx) covenants in our credit agreement could restrict our business and operations, (xxi) exposure to liquidity and counterparty risk as a result of financial institution and money market fund concentration, (xxii) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (xxiii) catastrophic events, (xxiv) Omnicell’s ability to recruit and retain skilled and motivated personnel, (xxv) Omnicell’s ability to protect its intellectual property, (xxvi) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xxvii) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, (xxviii) fluctuations in quarterly and annual operating results may make our future operating results difficult to predict, (xxix) failing to meet (or significantly exceeding) our publicly announced financial guidance, and (xxx) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Readers are encouraged to review this press release in conjunction with our most recent Annual Report on Form 10-K and our other reports filed with or furnished to the SEC. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.Non-GAAP Financial InformationThis presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), including Q3 ’26 non-GAAP gross margin, non-GAAP operating expenses, non-GAAP EBITDA, and non-GAAP diluted earnings per share, guidance with respect to 2026 non-GAAP EBITDA and non-GAAP earnings per share. Reconciliations of the Q3 ‘26 non-GAAP financial measures to the most directly comparable GAAP measures are included in the Appendix to this presentation. Our 2026 guidance for non-GAAP EBITDA and non-GAAP earnings per share, exclude certain items, which include, but are not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes. These excluded items may be significant. We do not provide a reconciliation of forward-looking non-GAAP guidance or targets to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. We believe such a reconciliation would imply a degree of precision that could be confusing or misleading to investors. These items may also have a material impact on GAAP earnings per share and GAAP net income in future periods. As such, these forward-looking non-GAAP financial measures are limited in their utility for evaluating our future operating results in accordance with GAAP.OMNICELL, the Omnicell logo, and ENLIVENHEALTH are registered trademarks of Omnicell, Inc. or one its subsidiaries.© 2026 Omnicell, Inc. 2 Forward-Looking Statements
Page 3
© 2026 Omnicell, Inc. 3 Omnicell Investment HighlightsInvestor Presentation – October 29, 2026 A recognized leader in medication management with a 30-year track record and an installed base that includes more than one-half of the top 300 U.S. health systems* Investing in SaaS and Expert Services in an effort to drive growth in recurring revenue, projected to be 22% of total revenue in 2026 Strong balance sheet should support growth initiatives and help drive sustainable and profitable growth Executing on our vision to deliver autonomous medication management solutions that drive meaningful customer outcomes and create stakeholder value With Omnicell Titan XT, powered by our OmniSphere platform, Omnicell is investing in a next generation automated dispensing system that is built to support evolving healthcare needs while delivering greater pharmacy control and nursing confidence for a growing enterprise *As defined by Definitive Healthcare.
Page 4
© 2026 Omnicell, Inc. 4 Omnicell’s Growth Strategy is to:Investor Presentation – October 29, 2026 CONNECTthe health network GROWwhere care is being delivered DISRUPTpharmacy care with innovation
Page 5
© 2026 Omnicell, Inc. 5 Healthcare’s Biggest Pressures Are ConvergingInvestor Presentation – October 29, 2026 5 YearsAverage duration of a drug shortage as of year end 2025 Annual U.S. cost of nonadherence — behind 33–69% of related hospitalizations ~$100BPeople injured by medication errors each year in the U.S. — $42B in annual estimated cost globally ~1.3MRise in pharmaceutical expenses — outpacing labor and purchased services +5%40%Nursing time spent on documentation contributing to burnout United States Pharmacopia, 2025Becker’s Hospital Review, 2025US Surgeon General Advisory, 2022 World Health Organization, 2024Journal of American Medical Directors,2024
Page 6
© 2026 Omnicell, Inc. 6 Medication Management Is an Enterprise DisciplineInvestor Presentation – October 29, 2026 At the heart of this transformation is autonomous medication management. Create a smoother experienceStrengthen medication availabilitySupport safer, more compliant processesReduce burden on care teamsConnect insight to financial performance
Page 7
© 2026 Omnicell, Inc. 7 Connecting the Medication Use ProcessInvestor Presentation – October 29, 2026 Optimize Medication Supply ChainReduce Administrative BurdenStrengthen Financial PerformanceEnhance Safety and ComplianceElevate Patient andStaff Experience OrderProcurementDispensingAdministrationTransition of CareAdherence and Disease ManagementRevenue Cycle
Page 8
© 2026 Omnicell, Inc. 8 Unlocking Clinical and Operational Excellence with OmnicellInvestor Presentation – October 29, 2026 Connected IntelligencePredictive DecisionsDisciplinedAction
Page 9
© 2026 Omnicell, Inc. 9 A Platform That Connects. A Portfolio That Delivers.Investor Presentation – October 29, 2026 OmniSphere, our cloud-based, connected platform, is designed to provide visibility, drive actionable insights, and deliver a unified user experience across the medication journey. Intelligence PlatformAutomation PortfolioOmniSphere AdministrationOne hub for users, devices and formularyIntelligenceInsights that help teams drive the next actionInventoryMedication visibility across sites and care settingCompliance SupportChain of custody and audit trails, built inInteroperabilityOne medication layer, across your EHRs Hospital Solutions•Central Pharmacy/Consolidated Service Centers Inventory Management•IV Compounding•Point of Care Medication Administration•Ambulatory Settings Outpatient Services•Specialty Pharmacy Managed Services•340B Program Management•Patient Engagement & Adherence Support•Community Pharmacy OptimizationAmbulatory SettingsInfrastructureCloud-native infrastructure protects and connectsthe medication journey
Page 10
© 2026 Omnicell, Inc. 10 From Orders to Outcomes: Real Health Systems.Real Results.*Investor Presentation – October 29, 2026 ~70%Time saved for cabinet restocking workflowIncrease in waste compliance28%$307KSavings in first9 months from improved inventory insight Annual specialty pharmacy revenue captured in year one $9.1MIncrease in pharmacist-led clinical interventions 41% * Reflects results or outcomes based on customer experiences or Omnicell’s internal data or analysis. Additional detail can be found in the case studies available at: https://www.omnicell.com/resources Discussion of potential benefits or expected outcomes does not imply, and Omnicell does not guarantee, that any specific impact or improvement will be achieved. Customer outcomes are dependent upon many different factors and individual results may vary.
Page 11
© 2026 Omnicell, Inc. 11 Revenue Growth DriversInvestor Presentation – October 29, 2026 Deep Customer Relationships Robust Product Backlog and Annual Recurring Revenue oStrong position with more than one-half of the top 300 U.S. health systems* oRobust Product Backlog of $640M as of 12/31/2025oAnnual Recurring Revenue of $636M as of 12/31/2025 Multiple Growth DriversoExpanding Our Market Presence Expand our footprint within our existing customer base and increasing market adoption of our products and solutions oScaling Recurring Revenue Grow our predictable recurring revenue base by increasing market adoption and delivering long-term value to customersoAccelerating Our Technology PlatformOmniSphere, a cloud-native platform that is designed to be the connected backbone for all Omnicell products, beginning on nursing floors with the launch of Omnicell Titan XT *As defined by Definitive Healthcare.
Page 12
© 2026 Omnicell, Inc. 12 Why We Believe Omnicell Is Positioned to WinInvestor Presentation – October 29, 2026 Omnicell has the right solutions and the right business model to solve the medication managementproblem that the healthcare system is facing Omnicell has a proven track record of innovation as the leading strategic partner to health systems in large and growingmarket segments Omnicell is scaling SaaS and Expert Services to capitalize on the many growth opportunities ahead — with SaaS and Expert Services continuing to drive recurringrevenue growth Continued investment in new products and solutions, including Omnicell Titan XT and OmniSphere to drive long-term sustainable growth Executing on our vision to advance autonomous medication management
Page 13
Third Quarter 2026Financial Highlights
Page 14
© 2026 Omnicell, Inc. 14 Financial SnapshotInvestor Presentation – October 29, 2026 Q3 ’26YoY Change Total Revenues$308 million(1%)Non-GAAP Gross Margin %45.4%120 bpsNon-GAAP Operating Expenses$108 million(2%)Non-GAAP EBITDA$45 million9%Non-GAAP Diluted Earnings Per Share$0.5814% See Appendix for a reconciliation of Q3 ‘26 Non-GAAP Gross Margin, Q3 ‘26 Non-GAAP Operating Expenses, Q3’26 Non-GAAP EBITDA and Q3’26 Non-GAAP Diluted Earnings Per Share to their most directly comparable GAAP financial measures.
Page 15
© 2026 Omnicell, Inc. 15 Total Year Revenue CompositionInvestor Presentation – October 29, 2026 1.Connected Devices and Software Licenses include, but are not limited to, XT Series automated dispensing systems and products related to Central Pharmacy Dispensing Service and IV Compounding Service.2.Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth solutions, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions. GAAP ($Million)Recurring vs Non RecurringCategoryActual 1Q26Actual 2Q26Actual 3Q26Guidance TY–2026TY 2026 YoY Change %(Mid-Point) Connected Devices and Software Licenses1Non RecurringProduct$149$149$146$684–$6873%ConsumablesRecurring Product $26$26$27 Technical ServicesRecurring Service $67$68$68$272–$2735% SaaS and Expert Services2 Recurring Service $68$69$67$269–$2714% Total Revenue $310$312$308$1,225–$1,2314% SaaS and Expert Services % of Total Revenue22%22%22%22% Recurring % of Total Revenue 52%52%53%
Page 16
© 2026 Omnicell, Inc. 2026 GuidanceInvestor Presentation – October 29, 2026 Long-Term Value Creation OpportunitiesoLeadership position in the digital transformation of healthcareoOmnicell’s Titan XT is designed to combine proven automation and powerful intelligence to deliver an enhanced medication management experienceoOmniSphere, a cloud-native platform designed to enable enterprise-wide medication visibility and simplify access to automation and intelligence toolsoPlatform adoption, expansion, market share gains, and upgrade cycles supporting growth oStrong balance sheet should enable transformation to new business model Q4–2026TY–2026Product bookingsNot guided$425–$560 millionARR Not guided$660–$670 millionTotal Revenues$295–$301 million$1.225–$1.231 billionProduct Revenues$161–$164 million$684–$687 millionService Revenues$134–$137 million$541–$544 millionTechnical Services RevenuesNot guided$272–$273 millionSaaS & Expert Services RevenuesNot guided$269–$271 millionNon-GAAP EBITDA$30–$36 million$187–$193 millionNon-GAAP EPS$0.41–$0.49$2.48–$2.56 We do not provide a reconciliation of forward-looking non-GAAP guidance to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. 16
Page 17
© 2026 Omnicell, Inc. An Outcomes-Based Approach to ESGInvestor Presentation – October 29, 2026 EnvironmentaloReduced Scope 1 emissions by 6%, Scope 2 location-based emissions by 4%, and energy consumption by 2% in 2025 oEnhanced Scope 1 and 2 GHG inventory methodology and completeness by incorporating additional emission sources, updating operational control boundaries, and expanding Scope 2 reporting to include market-based emissionsoCompleted a comprehensive Scope 3 baseline assessment using 2024 activity data and expanded the assessment to include 2025 activity data, covering relevant categories across our value chainoCommitted to achieve net zero emissions by 2050 for Omnicell Limited’s operations within the United KingdomSocialoStrengthened employee culture and engagement through our refreshed Employee Value Proposition, “Inspired by Care. Driven by Purpose. Delivered by You.,” and our first Culture Week, including a Global Give Back Challenge oDeveloped the Elevate Your Career framework to support employees’ professional growth and continued investing in our leaders through the Development Circles, Leader as Coach, Lead, and Insight 360 programsoReceived the National Kidney Foundation’s John V. Heher Humanitarian Award for community involvement, contributions supporting individuals with kidney disease, and leadership in kidney disease prevention and organ donation awarenessoissues, including kidney health, heart health, breast cancer awareness, domestic violence awareness, and moreGovernanceoEstablished the Omnicell Innovation Lab, a collaborative hub designed to rapidly develop and test solutions for customer-identified challenges across the medication and supply journey oEnhanced our customer training and education program, launched an online platform designed to educate and support customers in their automation journey, and renovated our training spaces to accommodate more customersoStrengthened compliance and supply chain due diligence efforts through an updated Code of Conduct, development of an annual compliance risk assessment process, enhanced conflict minerals reporting activities, and continued supplier surveys1. ISS ESG ”Prime” rating calculated as of September 26, 2025 1 17 2025 ESG ReportPublished sixth annual ESG Report in August 2026 89%of Board is independent Corporate Governance Awards2024 Report Awarded Best Sustainability Reporting (Small Cap) 2025 Report Shortlisted for Best Sustainability Reporting (Small Cap)
Page 18
Appendix
Page 19
© 2026 Omnicell, Inc. 19
Page 20
© 2026 Omnicell, Inc. 20 (a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2026 and 2025.
Page 21
© 2026 Omnicell, Inc. 21 (b) Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments.